Tumours demonstrating strong CYP46A1 immunostaining (n=173) had a mean patient survival of 87 months (95% CI 76-98) whereas negative/weak/moderate CYP46A1 immunostaining (n=452) was associated with a mean patient survival of 122 months (95% CI 112-131). The gene discussed is CYP46A1; the disease is neoplasm.